Method for detecting impurities in glycine methyl ester hydrochloride by high performance liquid chromatography
Detection of impurities in methyl glycine hydrochloride by high performance liquid chromatography, solving the problem that the quality of glycine methyl glycine hydrochloride cannot be effectively controlled in the prior art, and achieving efficient detection of impurities in methyl glycine hydrochloride, providing A valuable reference for the quality control of glycine methyl ester hydrochloride.
Patent Information
- Application Number
- CN202411212197.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art cannot effectively detect and control impurities in methyl glycine hydrochloride, resulting in an increase in drug use risk and lack of applicable quality control methods.
Using high performance liquid chromatography, the preparation of reference samples and system-applicable solutions of each component, combined with specific chromatographic columns and mobile phase conditions, achieve efficient detection of six impurities in methyl glycine hydrochloride, including 3-amino Separation and quantitative analysis of methyl propionate, methyl diglycine, methyl glycidylate, methyl serine, dimethyl aminobisacetate and ulotropine.
It realizes efficient detection of impurities in methyl glycine hydrochloride, with simple operation, good reproducibility, low detection limit, low detection limit, and recovery rate between 98% and 101%, providing a pair of methyl glycine hydrochloride A valuable reference for quality control.
Smart Images

Figure CN119044360A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medical detection, in particular to a method for detecting impurities in glycine methyl ester hydrochloride by high performance liquid chromatography. Background Art
[0002] Roxadustat is a new oral hypoxia-inducible factor prolyl hydroxylase inhibitor. It was approved for production in China in December 2018 and is mainly developed by AstraZeneca and FibroGen in the Chinese market. It is an oral drug mainly used to treat renal anemia. It can also be used to treat anemia in patients with dialysis-dependent chronic kidney disease (DD-CKD) and non-dialysis-dependent chronic kidney disease (NDD-CKD).
[0003] Glycine methyl ester hydrochloride, also known as aminoacetic acid methyl ester hydrochloride, is a key material for the preparation of roxadustat API. There are two main industrial production methods for glycine methyl ester hydrochloride, the glycine raw material method and the chloroacetic acid raw material method. At present, the glycine raw material method is mainly used in China, and the specific synthesis route is as follows:
[0004]
[0005] In the above synthesis, glycine and methanol are subjected to a synthesis reaction in a reactor, and hydrogen chloride methanol is added for esterification reaction. After filtration, crystallization, centrifugation, and vacuum drying, glycine methyl ester hydrochloride is obtained. Impurities such as 3-aminopropionic acid methyl ester, diglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester, and urotropine may be produced in the raw material of glycine methyl ester hydrochloride, but there are no reports on the determination of these impurities in glycine methyl ester hydrochloride raw materials at home and abroad. The chemical industry standard HG / T 3882-2006 uses potentiometric titration to determine the content of glycine ethyl ester hydrochloride, and it is impossible to control related impurities. When the raw material drug is applied for listing, the National Drug Evaluation Center will require the study of its related impurities. In order to effectively control the quality of glycine methyl ester hydrochloride and reduce the risk of drug use, we established a high-performance liquid chromatography method to determine the six impurities in glycine methyl ester hydrochloride, providing a valuable reference for the quality control of glycine methyl ester hydrochloride. Summary of the invention
[0006] The technical problem to be solved by the present invention is to overcome the deficiencies in the prior art and provide a method for detecting six impurities in glycine methyl ester hydrochloride by high performance liquid chromatography. The present invention is simple to operate, has high impurity separation, good reproducibility, has good practical application value, and plays a guiding role in the formulation and improvement of the quality standard of glycine methyl ester hydrochloride in the industry.
[0007] The technical solution adopted by the present invention to solve its technical problem is:
[0008] A method for detecting impurities in glycine methyl ester hydrochloride by high performance liquid chromatography comprises the following steps:
[0009] (1) Preparation of reference stock solutions of each component: weigh 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine, put them into the same container, dissolve them with a diluent and make up to the mark to obtain reference stock solutions of each component;
[0010] (2) Preparation of the secondary reference stock solution of each component: weigh the reference stock solution of each component, put it into a container, dissolve it with a diluent and make up to the mark to obtain the secondary reference stock solution of each component;
[0011] (3) Preparation of system suitability solution: Weigh glycine methyl ester hydrochloride and the above-mentioned secondary stock solutions of the components, put them into the same container, dissolve them with a diluent and make up to the mark to prepare the system suitability solution;
[0012] (4) Preparation of reference solution: Weigh 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and urotropine reference substance, and put them into 6 containers respectively. Dissolve each container with diluent and make up to the scale, shake well, and use them as reference solutions of each component;
[0013] (5) Preparation of test solution: Accurately weigh glycine methyl ester hydrochloride API into a container, add diluent to dissolve and dilute to scale;
[0014] (6) Chromatographic conditions
[0015] Detector: UV detector;
[0016] Chromatographic column: Octylsilane bonded silica gel is used as filler; the chromatographic column is Kromasil100-5-C8, and the chromatographic column specification is 5um, 250mm×4.6mm;
[0017] Detection wavelength: 200nm;
[0018] Column temperature: 40-50°C;
[0019] Mobile phase: sodium pentane sulfonate aqueous solution is used as mobile phase A, and methanol is used as mobile phase B; the concentration of the sodium pentane sulfonate aqueous solution is 0.01-0.02 mol / L, and the preparation method thereof is as follows: 1.7-3.4 g of sodium pentane sulfonate is dissolved and diluted with water, and the pH value is adjusted to 2.0-3.0 with phosphoric acid to obtain a sodium pentane sulfonate solution, which is filtered, and then the sodium pentane sulfonate solution and methanol are mixed in a volume ratio of 95:5, and ultrasonically degassed;
[0020] Isocratic elution for 25 min;
[0021] Flow rate: 1.0~1.2ml / min;
[0022] Injection volume: 5 μL;
[0023] (7) Determination method:
[0024] Accurately measure the diluent, system suitability solution, reference solution, and test solution, respectively, and inject them into the liquid chromatograph, and record the chromatogram; use the external standard method to calculate the impurity content and other unknown impurity content in the test solution;
[0025] In the chromatogram of the test solution of step (5), the chromatographic peaks consistent with the retention times of the six impurities in the obtained test solution are determined, and the peak areas calculated by the external standard method are that 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidic acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine are all less than 0.1%; other unknown impurities are calculated by the main component external standard method, and the single impurity does not exceed 0.10%, and the total amount of impurities does not exceed 1.0%.
[0026] Regarding the selection of mobile phase: Since glycine methyl ester hydrochloride and impurities are amphoteric compounds with high molecular polarity, they are basically unretained on ordinary C18 chromatographic columns. During the method development process, ion pair reagents need to be added. Considering factors such as the properties of the chromatographic column stationary phase, sodium pentane sulfonate was selected. The pentane group is adsorbed and combined with the chromatographic column stationary phase, exposing the sulfonic acid group anion, which can adsorb the cations in the analyte in the mobile phase, thereby enhancing the retention of ionic compounds.
[0027] Regarding the selection of chromatographic columns: Considering that glycine methyl ester hydrochloride and its impurities are weakly retained on ordinary octadecylsilane bonded silica gel columns, a water-resistant column is selected first. 100% aqueous phase can be used for detection, and the chromatographic peak separation is insufficient; then, considering the damage of the use of ion pair reagents to the chromatographic column, the proportion of organic phase is appropriately increased, and the cheapest octylsilane bonded silica gel column is selected for method development. The chromatographic peak has good symmetry and a stable baseline.
[0028] Regarding the selection of column temperature: As the column temperature increases, the peak elution time of each component is shortened. When the column temperature is 40°C, 45°C and 50°C, each impurity peak can achieve baseline separation, but considering the peak elution time factor, 45°C is preferred as the column temperature.
[0029] Furthermore, the diluent in step (1), step (2), step (3), step (4), step (5) and step (7) is water.
[0030] Furthermore, in the reference substance stock solutions of each component in step (1), the concentrations of 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and urotropine are 2 mg / mL respectively.
[0031] Furthermore, in the reference secondary stock solution of each component in step (2), the concentrations of 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and urotropine are 100 μg / mL respectively.
[0032] Furthermore, the concentrations of 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and urotropine in the component control solution of step (4) are 2 mg / mL respectively.
[0033] Furthermore, the concentration of glycine methyl ester hydrochloride raw material in the test solution of step (5) is 2 mg / mL.
[0034] The invention has the following beneficial effects: the invention has reasonable design and simple operation, and is suitable for detecting impurities in a sample of glycine methyl ester hydrochloride. A Kromasil 100-5-C8 chromatographic column (250 mm×4.6 mm, 5 um) is used, a 0.01 mol / L sodium pentane sulfonate aqueous solution is used as a mobile phase A, and methanol is used as a mobile phase B. Isocratic elution is performed, and 6 target substances are detected at a detection wavelength of 200 nm. It is obtained that the 6 target substances are linearly related to the corresponding peak areas within a certain mass concentration range, and the detection limit is low. A spike recovery test is performed on actual samples, and the obtained recovery rates are all between 98% and 101%. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0036] Figure 1 is the chromatogram of the system suitability solution. DETAILED DESCRIPTION
[0037] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.
[0038] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form also includes the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this description, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.
[0039] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0040] The present invention will be further described below in conjunction with the embodiments.
[0041] Example 1
[0042] A method for determining six impurities in glycine methyl ester hydrochloride by high performance liquid chromatography comprises the following steps:
[0043] (1) Chromatographic conditions
[0044] Chromatographic column: Kromasil 100-5-C8, column specifications: 5um, 250mm×4.6mm;
[0045] Detection wavelength: 200nm;
[0046] Column temperature: 45°C
[0047] Mobile phase A: 1.7 g sodium pentane sulfonate was diluted with 1000 mL water, and the pH value was adjusted to 2.0 with phosphoric acid to obtain a sodium pentane sulfonate solution, which was filtered and degassed by ultrasonication;
[0048] Mobile phase B: methanol;
[0049] Mobile phase A:mobile phase B = 95:5, isocratic elution for 25 min;
[0050] Flow rate: 1.0ml / min;
[0051] Injection volume: 5 μL.
[0052] Solvent: Water
[0053] (2) Preparation of reference stock solutions of each component: accurately weigh 20 mg each of 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine, put them into the same 10 mL volumetric flask, dissolve them with diluent and make up to the mark to obtain reference stock solutions of each component; the concentration of each component is 2 mg / mL;
[0054] (3) Preparation of secondary stock solutions of each component: Accurately measure 0.5 mL of the stock solution of each component, put it into a 10 mL volumetric flask, dissolve it with a diluent and make up to the mark to obtain the secondary stock solution of each component, with the concentration of each component being 100 μg / mL;
[0055] (4) Preparation of system suitability solution: Weigh 50 mg of glycine methyl ester hydrochloride and 0.5 mL of the secondary control stock solution of each component mentioned above, put them into the same 25 mL volumetric flask, dissolve them with diluent and make up to the mark to prepare the system suitability solution.
[0056] (5) Preparation of reference solution: Accurately weigh about 20 mg of each of the impurities 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and hexamethylenetetramine reference substance, and transfer them into six 10 mL volumetric flasks. Dissolve them in solvent and dilute to the mark. Shake well and use them as reference solutions for each component. The concentration of the reference solution for each component is 2 mg / mL.
[0057] (6) Preparation of test solution: Accurately weigh 50 mg of glycine methyl ester hydrochloride API into a 25 mL volumetric flask, add diluent to dissolve and dilute to the mark.
[0058] (7) Measurement method
[0059] Accurately measure 20 μL of each of the solvent, system suitability solution, reference solution, and test solution, and inject them into the liquid chromatograph to record the chromatogram.
[0060] In this embodiment, the solvent does not interfere with the detection of the present invention. In the system suitability solution, urotropine, glycine methyl ester, serine methyl ester, 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidic acid methyl ester and aminodiacetic acid dimethyl ester are peaked in sequence, and the separation between glycine methyl ester and adjacent impurity peaks is 2.80 and 1.83 respectively, and the minimum separation between each impurity is 1.56, which is greater than 1.5. It is explained that the main component and adjacent impurities in this method are well separated, so as to more accurately evaluate the product quality.
[0061] No known impurities were detected in the test solutions.
[0062] Example 2
[0063] This example is exactly the same as Example 1, except that the pH of the mobile phase in step (1) is replaced from 2.0 to 3.0. After the measurement, the chromatogram is recorded.
[0064] In this embodiment, the solvent does not interfere with the detection of the present invention. In the system suitability solution, urotropine, glycine methyl ester, serine methyl ester, 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidic acid methyl ester and aminodiacetic acid dimethyl ester are peaked in sequence, and the separation between glycine methyl ester and adjacent impurity peaks is 2.05 and 1.85, respectively, and the minimum separation between each impurity is 1.60, which is greater than 1.5. It is shown that the high pH in this method has no effect on the good separation between the main component and the adjacent impurities, and between each impurity, so as to more accurately evaluate the product quality.
[0065] No known impurities were detected in the test solutions.
[0066] Example 3
[0067] (1) Chromatographic conditions
[0068] Chromatographic column: Kromasil 100-5-C8, column specifications: 5um, 250mm×4.6mm;
[0069] Detection wavelength: 200nm;
[0070] Column temperature: 45°C
[0071] Mobile phase A: 1.7 g sodium pentane sulfonate was diluted with 1000 mL water, and the pH value was adjusted to 2.0 with phosphoric acid to obtain a sodium pentane sulfonate solution, which was filtered and degassed by ultrasonication;
[0072] Mobile phase B: methanol;
[0073] Mobile phase A:mobile phase B = 95:5, isocratic elution for 25 min;
[0074] Flow rate: 1.2 ml / min;
[0075] Injection volume: 5 μL.
[0076] Solvent: Water
[0077] (2) Preparation of reference stock solutions of each component: accurately weigh 20 mg each of 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine, put them into the same 10 mL volumetric flask, dissolve them with diluent and make up to the mark to obtain reference stock solutions of each component; the concentration of each component is 2 mg / mL;
[0078] (3) Preparation of secondary stock solutions of each component: Accurately measure 0.5 mL of the stock solution of each component, put it into a 10 mL volumetric flask, dissolve it with a diluent and make up to the mark to obtain the secondary stock solution of each component, with the concentration of each component being 100 μg / mL;
[0079] (4) Preparation of system suitability solution: 50 mg of glycine methyl ester hydrochloride and 0.5 mL of the secondary control stock solution of each component were weighed and placed in the same 25 mL volumetric flask. The system suitability solution was prepared by dissolving the solution with a diluent and adjusting the volume to the mark.
[0080] (5) Preparation of reference solution: Accurately weigh about 20 mg of each of the impurities 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and hexamethylenetetramine reference substance, and transfer them into six 10 mL volumetric flasks. Dissolve them in solvent and dilute to the mark. Shake well and use them as reference solutions for each component. The concentration of the reference solution for each component is 2 mg / mL.
[0081] (6) Preparation of test solution: Accurately weigh 50 mg of glycine methyl ester hydrochloride API into a 25 mL volumetric flask, add diluent to dissolve and dilute to the mark.
[0082] (7) Measurement method
[0083] Accurately measure 20 μL of each of the solvent, system suitability solution, reference solution, and test solution, and inject them into the liquid chromatograph to record the chromatogram.
[0084] In this embodiment, the system solution urotropine, glycine methyl ester, serine methyl ester, 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidic acid methyl ester and aminodiacetic acid dimethyl ester are peaked in sequence, and the separation degrees of glycine methyl ester and adjacent impurity peaks are 3.01 and 1.25 respectively, and the minimum separation degree between each impurity is 1.53, which is greater than 1.5. It is explained that although the high flow rate in this method leads to problems such as increased column pressure and shortened impurity peak retention time, it has no effect on the good separation of the main component and adjacent impurities, and between each impurity, so as to more accurately evaluate the product quality.
[0085] No known impurities were detected in the test solutions.
[0086] Example 4
[0087] (1) Chromatographic conditions
[0088] Chromatographic column: Kromasil 100-5-C8, column specifications: 5um, 250mm×4.6mm;
[0089] Detection wavelength: 200nm;
[0090] Column temperature: 40°C
[0091] Mobile phase A: 1.7 g sodium pentane sulfonate was diluted with 1000 mL water, and the pH value was adjusted to 2.0 with phosphoric acid to obtain a sodium pentane sulfonate solution, which was filtered and degassed by ultrasonication;
[0092] Mobile phase B: methanol;
[0093] Mobile phase A:mobile phase B = 95:5, isocratic elution for 25 min;
[0094] Flow rate: 1.2 ml / min;
[0095] Injection volume: 5 μL.
[0096] Solvent: Water
[0097] (2) Preparation of reference stock solutions of each component: accurately weigh 20 mg each of 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine, put them into the same 10 mL volumetric flask, dissolve them with diluent and make up to the mark to obtain reference stock solutions of each component; the concentration of each component is 2 mg / mL;
[0098] (3) Preparation of secondary stock solutions of each component: Accurately measure 0.5 mL of the stock solution of each component, put it into a 10 mL volumetric flask, dissolve it with a diluent and make up to the mark to obtain the secondary stock solution of each component, with the concentration of each component being 100 μg / mL;
[0099] (4) Preparation of system suitability solution: 50 mg of glycine methyl ester hydrochloride and 0.5 mL of the secondary control stock solution of each component were weighed and placed in the same 25 mL volumetric flask. The system suitability solution was prepared by dissolving the solution with a diluent and adjusting the volume to the mark.
[0100] (5) Preparation of reference solution: Accurately weigh about 20 mg of each of the impurities 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and hexamethylenetetramine reference substance, and transfer them into six 10 mL volumetric flasks. Dissolve them in solvent and dilute to the mark. Shake well and use them as reference solutions for each component. The concentration of the reference solution for each component is 2 mg / mL.
[0101] (6) Preparation of test solution: Accurately weigh 50 mg of glycine methyl ester hydrochloride API into a 25 mL volumetric flask, add diluent to dissolve and dilute to the mark.
[0102] (7) Measurement method
[0103] Accurately measure 20 μL of each of the solvent, system suitability solution, reference solution, and test solution, and inject them into the liquid chromatograph to record the chromatogram.
[0104] In this embodiment, the solvent does not interfere with the detection of the present invention. In the system suitability solution, urotropine, glycine methyl ester, serine methyl ester, 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidic acid methyl ester and aminodiacetic acid dimethyl ester are peaked in sequence, and the peak separations of glycine methyl ester and adjacent impurity peaks are 2.86 and 1.91, respectively, and the minimum separation between each impurity is 1.62, which is greater than 1.5. It is shown that although the low column temperature in this method has an effect on the column pressure and peak time of the chromatographic column, it has no effect on the good separation between the main component and adjacent impurities, and between each impurity, thereby more accurately evaluating the product quality.
[0105] No known impurities were detected in the test solutions.
[0106] Example 5
[0107] This example is exactly the same as Example 4, except that the column temperature in step (1) is replaced from 40° C. to 50° C. After the measurement, the chromatogram is recorded.
[0108] In this embodiment, the solvent does not interfere with the detection of the present invention. In the system suitability solution, urotropine, glycine methyl ester, serine methyl ester, 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidic acid methyl ester and aminodiacetic acid dimethyl ester are peaked in sequence, and the separation degrees of glycine methyl ester and adjacent impurity peaks are 2.42 and 1.33 respectively, and the minimum separation degree between each impurity is 1.46, which is greater than 1.2. It is shown that although the high column temperature in this method has an effect on the peak time of impurities, it has no effect on the good separation between the main component and adjacent impurities, and each impurity, thereby more accurately evaluating the product quality.
[0109] No known impurities were detected in the test solutions.
[0110] Example 6
[0111] (1) Chromatographic conditions
[0112] Chromatographic column: Kromasil 100-5-C8, column specifications: 5um, 250mm×4.6mm;
[0113] Detection wavelength: 200nm;
[0114] Column temperature: 45°C
[0115] Mobile phase A: 3.4 g sodium pentane sulfonate was diluted with 1000 mL water, and the pH value was adjusted to 2.0 with phosphoric acid to obtain a sodium pentane sulfonate solution, which was filtered and degassed by ultrasonication;
[0116] Mobile phase B: methanol;
[0117] Mobile phase A:mobile phase B = 95:5, isocratic elution for 25 min;
[0118] Flow rate: 1.2 ml / min;
[0119] Injection volume: 5 μL.
[0120] Solvent: Water
[0121] (2) Preparation of reference stock solutions of each component: accurately weigh 20 mg each of 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine, put them into the same 10 mL volumetric flask, dissolve them with diluent and make up to the mark to obtain reference stock solutions of each component; the concentration of each component is 2 mg / mL;
[0122] (3) Preparation of secondary stock solutions of each component: Accurately measure 0.5 mL of the stock solution of each component, put it into a 10 mL volumetric flask, dissolve it with a diluent and make up to the mark to obtain the secondary stock solution of each component, with the concentration of each component being 100 μg / mL;
[0123] (4) Preparation of system suitability solution: Weigh 50 mg of glycine methyl ester hydrochloride and 0.5 mL of the secondary control stock solution of each component mentioned above, put them into the same 25 mL volumetric flask, dissolve them with diluent and make up to the mark to prepare the system suitability solution.
[0124] (5) Preparation of reference solution: Accurately weigh about 20 mg of each of the impurities 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and hexamethylenetetramine reference substance, and transfer them into six 10 mL volumetric flasks. Dissolve them in solvent and dilute to the mark. Shake well and use them as reference solutions for each component. The concentration of the reference solution for each component is 2 mg / mL.
[0125] (6) Preparation of test solution: Accurately weigh 50 mg of glycine methyl ester hydrochloride API into a 25 mL volumetric flask, add diluent to dissolve and dilute to the mark.
[0126] (7) Measurement method
[0127] Accurately measure 20 μL of each of the solvent, system suitability solution, reference solution, and test solution, and inject them into the liquid chromatograph to record the chromatogram.
[0128] In this embodiment, the system solution urotropine, glycine methyl ester, serine methyl ester, 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidic acid methyl ester and aminodiacetic acid dimethyl ester are peaked in sequence, and the separation degrees of glycine methyl ester and adjacent impurity peaks are 2.82 and 1.86 respectively, and the minimum separation degree between each impurity is 1.57, which is greater than 1.5. It shows that the ion pair concentration in this method has no effect on the good separation between the main component and the adjacent impurities, and between each impurity, so as to more accurately evaluate the product quality.
[0129] No known impurities were detected in the test solutions.
[0130] Example 7
[0131] System suitability and instrument precision determination of this method
[0132] (1) The chromatographic conditions are exactly the same as those in Example 1;
[0133] (2) Preparation of reference stock solutions of each component: accurately weigh 20 mg each of 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine, put them into the same 10 mL volumetric flask, dissolve them with diluent and make up to the mark to obtain reference stock solutions of each component; the concentration of each component is 2 mg / mL;
[0134] (3) Preparation of secondary stock solutions of each component: Accurately measure 0.5 mL of the stock solution of each component, put it into a 10 mL volumetric flask, dissolve it with a diluent and make up to the mark to obtain the secondary stock solution of each component, with the concentration of each component being 100 μg / mL;
[0135] (4) Preparation of system suitability solution: Weigh 50 mg of glycine methyl ester hydrochloride and 0.5 mL of the secondary control stock solution of each component mentioned above, put them into the same 25 mL volumetric flask, dissolve them with diluent and make up to the mark to prepare the system suitability solution.
[0136] (5) Determination method:
[0137] The system suitability solution was injected 6 times continuously and the chromatogram was recorded. The separation degree between peaks, theoretical plate number, tailing factor, RSD of retention time of each peak, and RSD of peak area of each peak were examined.
[0138] The results show that under this condition, the separation between peaks is ≥1.5, the number of theoretical plates is ≥2000, the tailing factor is ≤2.0, the RSD of the retention time of each peak is ≤1%, the RSD of the main peak area is ≤2%, and the RSD of the impurity peak area is ≤10%. The results are shown in Table 1, and the chromatogram is shown in Figure 1 shown.
[0139] Table 1
[0140]
[0141]
[0142] Example 8
[0143] The quantitative limit and detection limit of the method of the present invention are determined by the following steps:
[0144] (1) The chromatographic conditions are exactly the same as those in Example 1;
[0145] (2) Preparation of reference solution: Accurately weigh about 20 mg of each of the impurities 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and hexamethylenetetramine reference substance, and transfer them into six 10 mL volumetric flasks. Dissolve them in solvent and dilute to the mark. Shake well and use them as reference solutions for each component. The concentration of the reference solution for each component is 2 mg / mL.
[0146] (3) Preparation of quantitative limit solution: Take the reference solution, dilute it to a specific concentration with a diluent, inject the sample, and record the spectrum until the peak signal-to-noise ratio (S / N) is ≥10, and calculate the quantitative limit and quantitative limit concentration of each component. Prepare 6 portions of quantitative limit solution, inject the sample, and record the spectrum. Calculate the RSD of the peak area of each component, as shown in Table 2. Under the specific concentration of the quantitative limit solution, the signal-to-noise ratio (S / N) is ≥10, and the peak area RSD of each peak in the 6 portions of the quantitative limit solution is ≤10%.
[0147] Table 2 Quantitation limit determination results
[0148]
[0149] (4) Preparation of detection limit solution: Take the quantification limit solution under the quantification limit, dilute it with diluent, inject it, record the spectrum, and when the signal-to-noise ratio (S / N) is ≥3, calculate the detection limit and detection limit concentration of each component. The detection limit determination results are shown in Table 3. At the specific concentration of the detection limit, the signal-to-noise ratio (S / N) is ≥3.
[0150] Table 3 Detection limit determination results
[0151] Element S / N value Detection limit concentration (ug / mL) Hexamethylenetetramine 3.029 1.011 L-Serine methyl ester hydrochloride 3.386 11.473 3-Aminopropionic acid methyl ester hydrochloride 4.58 15.018 Bisglycine methyl ester hydrochloride 5.21 1.276 Methyl glycidyl ester hydrochloride 4.48 0.656 Dimethyl aminodiacetate hydrochloride 3.10 9.877
[0152] Example 9
[0153] The linearity and range of the method of the present invention are determined by the following steps:
[0154] (1) The chromatographic conditions are exactly the same as those in Example 1;
[0155] (2) Preparation of reference stock solutions of each component: accurately weigh 20 mg each of 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine, put them into the same 10 mL volumetric flask, dissolve them with diluent and make up to the mark to obtain reference stock solutions of each component; the concentration of each component is 2 mg / mL;
[0156] (3) Preparation of secondary stock solutions of each component: Accurately measure 0.5 mL of the stock solution of each component, put it into a 10 mL volumetric flask, dissolve it with a diluent and make up to the mark to obtain the secondary stock solution of each component, with the concentration of each component being 100 μg / mL;
[0157] (4) Preparation of linear solution:
[0158] Take the secondary stock solution of the reference substance (100 μg / mL), accurately measure 0.2 mL, 0.5 mL, 0.8 mL, 1 mL, 1.5 mL and 2 mL respectively, place them in 50 mL volumetric flasks, dilute to the scale with water, and shake well.
[0159] Determination method: Accurately measure 20 μL and inject it into the liquid chromatograph, record the chromatogram, and make a standard curve with concentration C (x) versus peak area (y).
[0160] (5) The results showed that the components had a good linear relationship within the concentration range of 0.4 μg / mL to 4 μg / mL. The linear equation and correlation coefficient are shown in Table 4, where X represents concentration, Y represents peak area, and R represents the correlation regression coefficient.
[0161] Table 4 Linear equations and correlation coefficients
[0162]
[0163] Example 10
[0164] The accuracy of the present invention is determined by the following steps:
[0165] (1) The chromatographic conditions are exactly the same as those in Example 1;
[0166] (2) Preparation of reference stock solutions of each component: accurately weigh 20 mg each of 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine, put them into the same 10 mL volumetric flask, dissolve them with diluent and make up to the mark to obtain reference stock solutions of each component; the concentration of each component is 2 mg / mL;
[0167] (3) Preparation of secondary stock solutions of each component: Accurately measure 0.5 mL of the stock solution of each component, put it into a 10 mL volumetric flask, dissolve it with a diluent and make up to the mark to obtain the secondary stock solution of each component, with the concentration of each component being 100 μg / mL;
[0168] (4) Preparation of test solution: Accurately weigh 50 mg of glycine methyl ester hydrochloride API into a 25 mL volumetric flask, add diluent to dissolve and dilute to the mark.
[0169] (5) 80% limit spiked test solution: Accurately weigh 50.0 mg of glycine methyl ester hydrochloride and add it to a 25 mL volumetric flask. Add 0.4 mL of the secondary stock solution of each component reference substance and dilute to the mark with diluent. Prepare three replicates in parallel.
[0170] (6) 100% limit spiked test solution: Accurately weigh 50.0 mg of glycine methyl ester hydrochloride and add it to a 25 mL volumetric flask. Add 0.5 mL of the secondary stock solution of each component reference substance and dilute to the mark with diluent. Prepare three replicates in parallel.
[0171] (7) 120% limit spiked test solution: Accurately weigh 50.0 mg of glycine methyl ester hydrochloride and add it to a 25 mL volumetric flask. Add 0.6 mL of the secondary stock solution of each component reference substance and dilute to the mark with diluent. Prepare three replicates in parallel.
[0172] (8) Determination method:
[0173] Take the test sample, 80% limit spiked test sample solution, 100% limit spiked test sample solution, and 120% limit spiked test sample solution respectively, inject them into the liquid chromatograph, and record the chromatogram.
[0174] The content was calculated by external standard method, and the average recoveries of 9 determinations of impurities methyl iminodiacetate hydrochloride, methyl 3-aminopropionate hydrochloride, methyl L-serine hydrochloride, methyl bisglycine hydrochloride, methyl glycidyl hydrochloride and urotropine were 98.45%, 99.84%, 98.92%, 98.73%, 99.91% and 98.61%, respectively, and the RSD values were 1.16%, 0.79%, 1.13%, 0.87%, 0.74% and 0.97%, respectively. The results showed that the accuracy of the method was good.
[0175] In summary, the present invention has reasonable design and simple operation, and is suitable for detecting impurities in a sample of glycine methyl ester hydrochloride. A Kromasil 100-5-C8 chromatographic column (250 mm×4.6 mm, 5 um) is used, a 0.01 mol / L sodium pentane sulfonate aqueous solution (adjusted to pH 2.0 with phosphoric acid) is used as a mobile phase A, and methanol is used as a mobile phase B. Isocratic elution is performed, and 6 target substances are detected at a detection wavelength of 200 nm. It is obtained that the 6 target substances are linearly related to the corresponding peak areas within a certain mass concentration range, and the detection limit is low. A spike recovery test is performed on actual samples, and the obtained recovery rates are all between 98% and 101%.
[0176] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for detecting impurities in glycine methyl ester hydrochloride by high performance liquid chromatography, characterized in that: The following steps are involved: (1) Preparation of reference stock solutions of each component: weigh 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidyl acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine, put them into the same container, dissolve them with a diluent and make up to the mark to obtain reference stock solutions of each component; (2) Preparation of the secondary reference stock solution of each component: weigh the reference stock solution of each component, put it into a container, dissolve it with a diluent and make up to the mark to obtain the secondary reference stock solution of each component; (3) Preparation of system suitability solution: Weigh glycine methyl ester hydrochloride and the above-mentioned secondary stock solutions of the components, put them into the same container, dissolve them with a diluent and make up to the mark to prepare the system suitability solution; (4) Preparation of reference solution: Weigh 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and urotropine reference substance, and put them into 6 containers respectively. Dissolve each container with diluent and make up to the scale, shake well, and use them as reference solutions of each component; (5) Preparation of test solution: Accurately weigh glycine methyl ester hydrochloride API into a container, add diluent to dissolve and dilute to scale; (6) Chromatographic conditions Detector: UV detector; Chromatographic column: Octylsilane bonded silica gel is used as filler; the chromatographic column is Kromasil100-5-C8, and the chromatographic column specification is 5um, 250mm×4.6mm; Detection wavelength: 200nm; Column temperature: 40-50°C; Mobile phase: sodium pentane sulfonate aqueous solution is used as mobile phase A, and methanol is used as mobile phase B; the concentration of the sodium pentane sulfonate aqueous solution is 0.01-0.02 mol / L, and the preparation method thereof is as follows: 1.7-3.4 g of sodium pentane sulfonate is dissolved and diluted with water, and the pH value is adjusted to 2.0-3.0 with phosphoric acid to obtain a sodium pentane sulfonate solution, which is filtered, and then the sodium pentane sulfonate solution and methanol are mixed in a volume ratio of 95:5, and ultrasonically degassed; Isocratic elution for 25 min; Flow rate: 1.0~1.2ml / min; Injection volume: 5 μL; (7) Determination method: Accurately measure the diluent, system suitability solution, reference solution, and test solution, respectively, and inject them into the liquid chromatograph, and record the chromatogram; use the external standard method to calculate the impurity content and other unknown impurity content in the test solution; In the chromatogram of the test solution of step (5), the chromatographic peaks consistent with the retention times of the six impurities in the obtained test solution are determined, and the peak areas calculated by the external standard method are that 3-aminopropionic acid methyl ester, bisglycine methyl ester, glycidic acid methyl ester, serine methyl ester, aminodiacetic acid dimethyl ester and urotropine are all less than 0.1%; other unknown impurities are calculated by the main component external standard method, and the single impurity does not exceed 0.10%, and the total amount of impurities does not exceed 1.0%.
2. The method for detecting impurities in glycine methyl ester hydrochloride by high performance liquid chromatography according to claim 1, characterized in that: The diluent in steps (1), (2), (3), (4), (5) and (7) is water.
3. The method for detecting impurities in glycine methyl ester hydrochloride by high performance liquid chromatography according to claim 1, characterized in that: In the reference substance stock solutions of each component in step (1), the concentrations of 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and urotropine are 2 mg / mL respectively.
4. The method for detecting impurities in glycine methyl ester hydrochloride by high performance liquid chromatography according to claim 1, characterized in that: In the reference secondary stock solution of each component in step (2), the concentrations of 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and urotropine are 100 μg / mL respectively.
5. The method for detecting impurities in glycine methyl ester hydrochloride by high performance liquid chromatography according to claim 1, characterized in that: The concentrations of 3-aminopropionic acid methyl ester hydrochloride, bisglycine methyl ester hydrochloride, glycidyl acid methyl ester hydrochloride, L-serine methyl ester hydrochloride, aminodiacetic acid dimethyl ester hydrochloride and urotropine in the reference solution of step (4) are 2 mg / mL respectively.
6. The method for detecting impurities in glycine methyl ester hydrochloride by high performance liquid chromatography according to claim 1, characterized in that: The concentration of glycine methyl ester hydrochloride raw material in the test solution of step (5) is 2 mg / mL.
Citation Information
Cited By
Method for simultaneously determining contents of glycine methyl ester hydrochloride and 2, 5-piperazine diketone
CN121141884A
